Added to YB: 2026-02-11
Pitch date: 2026-02-06
NOVO-B.CO [neutral]
Novo Nordisk A/S
-22.72%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 306.56
Price Target
N/A
Dividend
4.94%
EV/EBITDA
7.46
P/E
10.29
EV/Sales
3.74
Sector
Pharmaceuticals
Category
value
Show full summary:
Theodosian Capital | Stocks Update 6/2/2026 - NOVOB – Disappointing guidance
NOVO-B.CO (update): Sales +10% CER but op profit -1% DKK on DKK8bn transformation costs. 2026 guidance disappointing: revenues/profits -5 to -13% CER due to intense competition, FX adds -3pts sales/-5pts earnings. New Wegovy up to 50k US prescriptions. DKK15bn buyback despite challenges. 13.4x 2027 P/E, 4% yield.
Read full article (2 min)